EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Biomolecular Predictors of Recurrence Patterns and Survival in IDH-Wild-Type Glioblastoma: A Retrospective Analysis of Patients Treated with Radiotherapy and Temozolomide

Paolo Tini, Flavio Donnini, Francesco Marampon, Marta Vannini, Tommaso Carfagno, Pierpaolo Pastina, Giovanni Rubino, Salvatore Chibbaro, Alfonso Cerase iD, Giulio Bagnacci, Armando Perrella iD, Maria Antonietta Mazzei iD und 4 weitere

Brain Sciences · 02.07.2025 · 15 (7) · 713

DOI: 10.3390/brainsci15070713 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain Sciences, online erschienen am 02.07.2025. Verfasst von Paolo Tini und 15 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Radiation Oncology, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, Italy. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim: Glioblastoma (GBM) is the most aggressive primary brain tumor in adults, with poor prognosis despite maximal surgical resection, radiotherapy (RT), and temozolomide (TMZ) per the Stupp protocol. IDH-wild-type GBM, the predominant molecular subtype, frequently harbors EGFR amplification and is resistant to therapy, while MGMT promoter methylation predicts improved TMZ response. This study aimed to assess the prognostic impact of EGFR and MGMT status on survival and recurrence patterns in IDH-wild-type GBM. Materials and Methods: We retrospectively analyzed 218 patients with IDH-wild-type GBM treated at the Azienda Ospedaliero-Universitaria Senese (2016–2024). All patients underwent maximal safe surgical resection whenever feasible. The cohort includes patients who received gross total resection (GTR), subtotal resection (STR), or biopsy only, depending on tumor location and clinical condition, followed by intensity-modulated RT (59.4–60 Gy) with concurrent and adjuvant TMZ. EGFR amplification was assessed via FISH/NGS and immunohistochemistry; MGMT promoter methylation was determined using methylation-specific PCR. Progression-free survival (PFS), overall survival (OS), and recurrence patterns (in-field, marginal, out-field) were evaluated using Kaplan–Meier, Cox regression, and logistic regression analyses.

Results

Among patients (64.7% male; mean age 61.8), 58.7% had EGFR amplification and 49.1% showed MGMT methylation. Median OS and PFS were 14 and 8 months, respectively. EGFR non-amplified/MGMT methylated tumors had the best outcomes (OS: 22.0 months, PFS: 10.5 months), while EGFR-amplified/MGMT unmethylated tumors fared worst (OS: 10.0 months, PFS: 5.0 months; p < 0.001). MGMT methylation was an independent positive prognostic factor (HR: 0.48, p < 0.001), while EGFR amplification predicted worse survival (HR: 1.57, p = 0.02) and higher marginal recurrence (OR: 2.42, p = 0.01).

Conclusions

EGFR amplification and MGMT methylation significantly influence survival and recurrence dynamics in IDH-wild-type GBM. Incorporating these biomarkers into treatment planning may enable tailored therapeutic strategies, potentially improving outcomes in this challenging disease. Prospective studies are needed to validate biomolecularly guided management approaches.

Schlagwörter

Stichwörter der Autor:innen

EGFRMGMTglioblastomapattern of recurrenceradiotherapy

Autor:innen und Institutionen

  • Unit of Radiation Oncology, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, Italy.
  • Radiation Oncology, Policlinico Umberto I, Department of Radiological, Oncological and Pathological Sciences, "Sapienza" University of Rome, 00185 Rome, Italy.
  • Neurosurgery, Azienda Ospedaliera Universitaria Senese, 53100 Siena, Italy.
  • Unit of Neuroradiology, Azienda Ospedaliera Universitaria Senese, 53100 Siena, Italy.
  • Unit of Diagnostic Imaging, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, Italy.
  • Center for Immuno-Oncology, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, Italy.

ORCID-Profile: Alfonso Cerase, Armando Perrella, Maria Antonietta Mazzei, Vincenzo D'Alonzo, Giuseppe Minniti

Zitieren

APA

Tini, P., Donnini, F., Marampon, F., Vannini, M., Carfagno, T., Pastina, P., Rubino, G., Chibbaro, S., Cerase, A., Bagnacci, G., Perrella, A., Mazzei, M. A., Pascucci, A., D'Alonzo, V., Giacomo, A. M. D., & Minniti, G. (2025). Biomolecular Predictors of Recurrence Patterns and Survival in IDH-Wild-Type Glioblastoma: A Retrospective Analysis of Patients Treated with Radiotherapy and Temozolomide. Brain Sciences, 15(7), 713. https://doi.org/10.3390/brainsci15070713

Vancouver

Tini P, Donnini F, Marampon F, Vannini M, Carfagno T, Pastina P, et al. Biomolecular Predictors of Recurrence Patterns and Survival in IDH-Wild-Type Glioblastoma: A Retrospective Analysis of Patients Treated with Radiotherapy and Temozolomide. Brain Sciences. 2025;15(7):713. doi:10.3390/brainsci15070713

BibTeX
@article{Tini2025,
  author = {Tini, Paolo and Donnini, Flavio and Marampon, Francesco and Vannini, Marta and Carfagno, Tommaso and Pastina, Pierpaolo and Rubino, Giovanni and Chibbaro, Salvatore and Cerase, Alfonso and Bagnacci, Giulio and Perrella, Armando and Mazzei, Maria Antonietta and Pascucci, Alessandra and D'Alonzo, Vincenzo and Giacomo, Anna Maria Di and Minniti, Giuseppe},
  title = {Biomolecular Predictors of Recurrence Patterns and Survival in IDH-Wild-Type Glioblastoma: A Retrospective Analysis of Patients Treated with Radiotherapy and Temozolomide},
  journal = {Brain Sciences},
  year = {2025},
  volume = {15},
  number = {7},
  pages = {713},
  doi = {10.3390/brainsci15070713}
}
Kostenlos starten →